Bone Turnover in Osteoporotic Patients Treated with Bisphosphonates
Author Information
Author(s): Eekman Danielle A, Bultink Irene EM, Heijboer Annemieke C, Dijkmans Ben AC, Lems Willem F
Primary Institution: VU University Medical Center
Hypothesis
Can monitoring bone turnover markers (BTMs) improve compliance in osteoporosis treatment?
Conclusion
Most patients treated with bisphosphonates showed a significant decrease in bone turnover markers, indicating effective treatment.
Supporting Evidence
- In the first group, 81% of patients showed a decrease in bone turnover markers greater than the least significant change.
- In the second group, 95% of patients had serum levels of bone turnover markers in the lower half of the premenopausal range.
- The study demonstrated that monitoring bone turnover markers is feasible in daily practice.
Takeaway
This study shows that checking certain blood markers can help doctors see if osteoporosis treatment is working and encourage patients to stick to their medicine.
Methodology
Patients were divided into two groups: newly diagnosed patients starting treatment and those already on bisphosphonates for at least three months. Blood samples were taken to measure BTMs.
Potential Biases
Potential bias due to self-reported compliance and the lack of standardized compliance measurement.
Limitations
The sample size for newly treated patients was relatively small, and compliance was self-reported.
Participant Demographics
The study included 126 patients, primarily elderly women, with a mean age of 66 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website